Patients with ER-α66-positive breast cancer generally respond favorably to endocrine therapy; however, approximately 40% of such cancers do not respond to tamoxifen therapy. A novel variant of ...

Tamoxifen is one of the most commonly used endocrine therapeutic agents for the treatment of estrogen receptor (ER)-positive breast cancer and is classified as a selective ER modulator, because it ...